Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 77, 29-41
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast CancerCancer Discovery, 2012
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinomaLaboratory Investigation, 2012
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian CancerJournal of Clinical Oncology, 2012
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- “Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA RepairClinical Cancer Research, 2010
- Genomic targets of the human c-Myc proteinGenes & Development, 2003